Trial description:
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk
Contact name:
Dr Kate Fife
Trial start date:
Friday, December 6, 2019
Trial end date:
Saturday, March 1, 2025
Trial tumour type:
Kidney
Show on Radiotherapy:
No
